The MyAction LifeNote study
Research type
Research Study
Full title
To evaluate the role of LifeNote in rates of medicine adherence and also its acceptability in patients at high multifactorial risk of developing cardiovascular disease attending the MyAction Westminster programme
IRAS ID
131456
Contact name
SB Connolly
Contact email
Sponsor organisation
Joint Research Compliance Office
Research summary
Achieving desirable blood pressure and cholesterol levels in every day clinical practice is far from ideal. There are many reasons for this but an important one is patient’s not adhering to their medication. This includes taking it at the wrong time, missing doses or stopping it altogether. This results in an increased risk of heart disease/stroke in the longer term. Effective strategies that help patients adhere better to their medication are still lacking. Such strategies are urgently needed to help improvement not just in the prevention of heart disease/stroke but also in other areas of chronic disease management.
LifeNote is a system which permits a patient to monitor taking his medication electronically. Alongside his/her usual medication, the patient also ingests a LifeNote pill. Once this comes in contact with the stomach acid, it emits a signal to a sensor patch the patient wears on his/her skin. This is then transmitted by bluetooth technology to a tablet device where the patient can see his/her medication taking schedule. The system also includes the capability for sending reminder text messages if the patient does not take his medication at the correct time.
We want to explore this device in 20 patients attending a community-based vascular prevention programme specifically in those already taking blood pressure or cholesterol lowering medication. We want to examine how adherent patient are to their medication whilst using the LifeNote system and we also want to examine how patients feel about using the device (i.e. is acceptable/useful in their opinion? etc). The patients will use the system for the duration of the MyAction programme which typically lasts about 12 weeks.REC name
London - Surrey Borders Research Ethics Committee
REC reference
13/LO/1279
Date of REC Opinion
10 Sep 2013
REC opinion
Further Information Favourable Opinion